Q1 2021

Source filing unavailable

Q1 2021 · —

Revenue—

Net Income

-$4.49M

N/M vs Q1 2020

EPS Diluted

-$0.97

no prior Q1 2020 on file

Operating Income-$449,465—

Operating Cash Flow-$522,153—

Free Cash Flowderived-$597,454—

Same quarter

Metric	Q1 2021	Q1 2020
Net Income	-$4.49M	-$41.26K
EPS Diluted	-$0.97	—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Transcode Therapeutics, Inc. · CIK 1829635 · Engraved from SEC EDGAR